Revenue Recognition and Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2021

Revenue Recognition and Collaborative Arrangements

Schedule of net revenue from collaborative arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2021		2020		2021		2020
Royalties from a related party - RELVAR/BREO	$	65,916	$	45,570	$	122,306	$	101,719
Royalties from a related party - ANORO		11,960		11,199		22,460		21,049
Royalties from a related party - TRELEGY		26,386		15,633		48,470		31,768
Total royalties from a related party		104,262		72,402		193,236		154,536
Less: amortization of capitalized fees paid to a related party		(3,456)		(3,456)		(6,912)		(6,912)
Royalty revenue		100,806		68,946		186,324		147,624
Strategic alliance  - MABA program		—		10,000		—		10,000
Total net revenue from GSK	$	100,806	$	78,946	$	186,324	$	157,624